

HervÃ© Dombret

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5007366/publications.pdf>

Version: 2024-02-01

136
papers

20,418
citations

50244

46
h-index

16164

124
g-index

137
all docs

137
docs citations

137
times ranked

16813
citing authors

#	ARTICLE	IF	CITATIONS
1	Machine learning identifies the independent role of dysplasia in the prediction of response to chemotherapy in AML. <i>Leukemia</i> , 2022, 36, 656-663.	3.3	6
2	The Evolution of Research and Therapy With Hypomethylating Agents in Acute Myeloid Leukemia and Myelodysplastic Syndrome: New Directions for Old Drugs. <i>Cancer Journal (Sudbury, Mass)</i> , 2022, 28, 29-36.	1.0	5
3	Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status. <i>Blood</i> , 2022, 139, 2145-2155.	0.6	38
4	Prognostic impact of <i>ABCA3</i> expression in adult and pediatric acute myeloid leukemia: an ALFA-ELAM02 joint study. <i>Blood Advances</i> , 2022, 6, 2773-2777.	2.5	3
5	Concurrent <i>CDX2</i> cis-deregulation and <i>UBTF::ATXN7L3</i> fusion define a novel high-risk subtype of B-cell ALL. <i>Blood</i> , 2022, 139, 3505-3518.	0.6	13
6	High tumor burden before blinatumomab has a negative impact on the outcome of adult patients with B-cell precursor acute lymphoblastic leukemia. A real-world study by the GRAALL. <i>Haematologica</i> , 2022, , .	1.7	10
7	Daunorubicin and Its Active Metabolite Pharmacokinetic Profiles in Acute Myeloid Leukaemia Patients: A Pharmacokinetic Ancillary Study of the BIG-1 Trial. <i>Pharmaceutics</i> , 2022, 14, 792.	2.0	0
8	Prognostic impact of <i>DDX41</i> germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO study. <i>Blood</i> , 2022, 140, 756-768.	0.6	48
9	Cystine uptake inhibition potentiates front-line therapies in acute myeloid leukemia. <i>Leukemia</i> , 2022, 36, 1585-1595.	3.3	24
10	A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia. <i>Nature Medicine</i> , 2022, 28, 1212-1223.	15.2	104
11	<i>IKZF1</i> alterations predict poor prognosis in adult and pediatric T-ALL. <i>Blood</i> , 2021, 137, 1690-1694.	0.6	8
12	A transcriptomic continuum of differentiation arrest identifies myeloid interface acute leukemias with poor prognosis. <i>Leukemia</i> , 2021, 35, 724-736.	3.3	8
13	Synergy of FLT3 inhibitors and the small molecule inhibitor of LIM kinase1/2 <i>CEL Amide</i> in FLT3-ITD mutated Acute Myeloblastic Leukemia (AML) cells. <i>Leukemia Research</i> , 2021, 100, 106490.	0.4	6
14	Long-term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab. <i>Cancer</i> , 2021, 127, 554-559.	2.0	21
15	A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemia. <i>Blood</i> , 2021, 137, 524-532.	0.6	33
16	Prognostic significance of concurrent gene mutations in intensively treated patients with <i>IDH</i> -mutated AML, an ALFA study. <i>Blood</i> , 2021, 137, 2827-2837.	0.6	36
17	Minimal residual disease quantification in ovarian tissue collected from patients in complete remission of acute leukemia. <i>Blood</i> , 2021, 137, 1697-1701.	0.6	15
18	Epigenetic analysis of patients with T-ALL identifies poor outcomes and a hypomethylating agent-responsive subgroup. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	13

#	ARTICLE	IF	CITATIONS
19	Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy. <i>Blood</i> , 2021, 138, 507-519.	0.6	40
20	Oncogenetic landscape and clinical impact of IDH1 and IDH2 mutations in T-ALL. <i>Journal of Hematology and Oncology</i> , 2021, 14, 74.	6.9	10
21	PRC2 loss of function confers a targetable vulnerability to BET proteins in T-ALL. <i>Blood</i> , 2021, 138, 1855-1869.	0.6	23
22	Actinomycin D Targets NPM1c-Primed Mitochondria to Restore PML-Driven Senescence in AML Therapy. <i>Cancer Discovery</i> , 2021, 11, 3198-3213.	7.7	38
23	Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase 3, placebo-controlled QUAZAR AML-001 trial. <i>Haematologica</i> , 2021, 106, 3240-3244.	1.7	6
24	Minimal residual disease monitoring in acute myeloid leukemia with non-A/B/D-NPM1 mutations by digital polymerase chain reaction: feasibility and clinical use. <i>Haematologica</i> , 2021, 106, 1767-1769.	1.7	8
25	Early detection of <i>WT1</i> measurable residual disease identifies high-risk patients, independent of transplantation in AML. <i>Blood Advances</i> , 2021, 5, 5258-5268.	2.5	12
26	Frequency and Outcome of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with BCR-ABL1 Clonal Hematopoiesis after Blast Clearance: Results from the Graaph-2014 Trial. <i>Blood</i> , 2021, 138, 3478-3478.	0.6	3
27	Impact of Central Nervous System Involvement in Adult Patients with Acute Lymphoblastic Leukemia Treated in a Pediatrics-Inspired Protocol - a Graall Study. <i>Blood</i> , 2021, 138, 215-215.	0.6	1
28	Replacing the Anthracycline By Gemtuzumab Ozogamicin in Older Patients with De Novo Standard-Risk Acute Myeloid Leukemia Treated Intensively - Results of the Randomized ALFA1401-Mylofrance 4 Study. <i>Blood</i> , 2021, 138, 31-31.	0.6	4
29	Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukemia. <i>Cancer</i> , 2020, 126, 304-310.	2.0	49
30	Biomarkers of Gemtuzumab Ozogamicin Response for Acute Myeloid Leukemia Treatment. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5626.	1.8	20
31	Horizontal meta-analysis identifies common deregulated genes across AML subgroups providing a robust prognostic signature. <i>Blood Advances</i> , 2020, 4, 5322-5335.	2.5	8
32	The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies. <i>Cancer Discovery</i> , 2020, 10, 1894-1911.	7.7	13
33	Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission. <i>New England Journal of Medicine</i> , 2020, 383, 2526-2537.	13.9	265
34	Low level CpG island promoter methylation predicts a poor outcome in adult T-cell acute lymphoblastic leukemia. <i>Haematologica</i> , 2020, 105, 1575-1581.	1.7	10
35	Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results. <i>Blood Advances</i> , 2020, 4, 1942-1949.	2.5	49
36	Vitamin D Receptor Controls Cell Stemness in Acute Myeloid Leukemia and in Normal Bone Marrow. <i>Cell Reports</i> , 2020, 30, 739-754.e4.	2.9	32

#	ARTICLE	IF	CITATIONS
37	Adult T-cell acute lymphoblastic leukemias with IL7R pathway mutations are slow-responders who do not benefit from allogeneic stem-cell transplantation. <i>Leukemia</i> , 2020, 34, 1730-1740.	3.3	21
38	Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia. <i>Blood</i> , 2020, 135, 542-546.	0.6	62
39	Outcome and clinicophenotypical features of acute lymphoblastic leukemia/lymphoblastic lymphoma with cutaneous involvement: A multicenter case series. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1166-1170.	0.6	6
40	Thromboembolism Prophylaxis in Adult Patients with Acute Lymphoblastic Leukemia Treated in the GRAALL-2005 Study. <i>Blood</i> , 2020, 136, 328-338.	0.6	23
41	Comparison of a Combination of Vosaroxin (VOS) and Intermediate-Dose Cytarabine (IDAC) with Idac for the Consolidation Therapy of Younger Patients with Favorable- and Intermediate-Risk Acute Myeloid Leukemia (AML) in First Complete Remission (CR): Preliminary Results of a Randomized Phase 2 R4-VOS Study of the French ALFA-Filo AML Intergroup. <i>Blood</i> , 2020, 136, 10-11.	0.6	0
42	Very Long Term Follow up a Phase II Study of Post-Remission Subcutaneous (SC) Azacitidine (AZA) in Patients with AML Post-MDS or Higher-Risk (HR) MDS. <i>Blood</i> , 2020, 136, 1-2.	0.6	0
43	Gemtuzumab ozogamicin for <i>de novo</i> acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial. <i>Haematologica</i> , 2019, 104, 113-119.	1.7	226
44	Chromosomal Abnormalities and Prognosis in <i>NPM1</i> -Mutated Acute Myeloid Leukemia: A Pooled Analysis of Individual Patient Data From Nine International Cohorts. <i>Journal of Clinical Oncology</i> , 2019, 37, 2632-2642.	0.8	77
45	Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements. <i>Blood</i> , 2019, 134, 1351-1355.	0.6	89
46	Epigenetic Silencing Affects Asparaginase Sensitivity and Predicts Outcome in T-ALL. <i>Clinical Cancer Research</i> , 2019, 25, 2483-2493.	3.2	25
47	<i>DNMT3A</i> mutation is associated with increased age and adverse outcome in adult T-cell acute lymphoblastic leukemia. <i>Haematologica</i> , 2019, 104, 1617-1625.	1.7	40
48	Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2019, 60, 2214-2222.	0.6	40
49	Clinical and biological features of PTPN2-deleted adult and pediatric T-cell acute lymphoblastic leukemia. <i>Blood Advances</i> , 2019, 3, 1981-1988.	2.5	12
50	Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemia. <i>Blood Advances</i> , 2019, 3, 3033-3037.	2.5	16
51	PAX5 P80R mutation identifies a novel subtype of B-cell precursor acute lymphoblastic leukemia with favorable outcome. <i>Blood</i> , 2019, 133, 280-284.	0.6	48
52	Sensitive Monitoring of BCR-ABL1 Kinase Domain Mutations By Next Generation Sequencing for Optimizing Clinical Decisions in Philadelphia-Positive Acute Lymphoblastic Leukemia in the Graaph-2014 Trial. <i>Blood</i> , 2019, 134, 1295-1295.	0.6	4
53	Clinical relevance of <i>IDH1/2</i> mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group. <i>Haematologica</i> , 2018, 103, 822-829.	1.7	36
54	Clonal interference of signaling mutations worsens prognosis in core-binding factor acute myeloid leukemia. <i>Blood</i> , 2018, 132, 187-196.	0.6	54

#	ARTICLE	IF	CITATIONS
55	Intensified Therapy of Acute Lymphoblastic Leukemia in Adults: Report of the Randomized GRAALL-2005 Clinical Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 2514-2523.	0.8	99
56	Deletion 6q Drives T-cell Leukemia Progression by Ribosome Modulation. <i>Cancer Discovery</i> , 2018, 8, 1614-1631.	7.7	30
57	Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2018, 19, 889-903.	5.1	205
58	Efficacy and Safety of Single-Agent Quizartinib (Q), a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) with FLT3-Internal Tandem Duplication (FLT3-ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled Quantum-R Trial. <i>Blood</i> , 2018, 132, 563-563.	0.6	26
59	SNP-array lesions in core binding factor acute myeloid leukemia. <i>Oncotarget</i> , 2018, 9, 6478-6489.	0.8	15
60	Epidemiology of invasive fungal infections during induction therapy in adults with acute lymphoblastic leukemia: a GRAALL-2005 study. <i>Leukemia and Lymphoma</i> , 2017, 58, 586-593.	0.6	47
61	Randomized Phase II Study of Clofarabine-Based Consolidation for Younger Adults With Acute Myeloid Leukemia in First Remission. <i>Journal of Clinical Oncology</i> , 2017, 35, 1223-1230.	0.8	37
62	Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. <i>New England Journal of Medicine</i> , 2017, 376, 836-847.	13.9	1,443
63	Hyper-CVAD + epratuzumab as a salvage regimen for younger patients with relapsed/refractory CD22-positive precursor B-cell acute lymphocytic leukemia. <i>Haematologica</i> , 2017, 102, e184-e186.	1.7	6
64	Hypomethylating Agents as a Therapy for AML. <i>Current Hematologic Malignancy Reports</i> , 2017, 12, 1-10.	1.2	47
65	Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. <i>Blood</i> , 2017, 129, 424-447.	0.6	4,375
66	Impact of cytogenetic abnormalities in adults with Ph-negative B-cell precursor acute lymphoblastic leukemia. <i>Blood</i> , 2017, 130, 1832-1844.	0.6	66
67	Postinduction Minimal Residual Disease Predicts Outcome and Benefit From Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia With <i>NPM1</i> Mutation: A Study by the Acute Leukemia French Association Group. <i>Journal of Clinical Oncology</i> , 2017, 35, 185-193.	0.8	227
68	Early Response-Based Therapy Stratification Improves Survival in Adult Early Thymic Precursor Acute Lymphoblastic Leukemia: A Group for Research on Adult Acute Lymphoblastic Leukemia Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 2683-2691.	0.8	134
69	An early thymic precursor phenotype predicts outcome exclusively in HOXA-overexpressing adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study. <i>Haematologica</i> , 2016, 101, 732-740.	1.7	53
70	International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia. <i>Haematologica</i> , 2016, 101, 1524-1533.	1.7	154
71	A 17-gene stemness score for rapid determination of risk in acute leukaemia. <i>Nature</i> , 2016, 540, 433-437.	13.7	617
72	An update of current treatments for adult acute myeloid leukemia. <i>Blood</i> , 2016, 127, 53-61.	0.6	444

#	ARTICLE	IF	CITATIONS
73	Comprehensive mutational profiling of core binding factor acute myeloid leukemia. <i>Blood</i> , 2016, 127, 2451-2459.	0.6	198
74	The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia. <i>Blood</i> , 2016, 127, 2157-2160.	0.6	60
75	Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosomeâ€“positive ALL. <i>Blood</i> , 2016, 128, 774-782.	0.6	243
76	Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia. <i>New England Journal of Medicine</i> , 2016, 375, 1044-1053.	13.9	270
77	Triggering the TCR Developmental Checkpoint Activates a Therapeutically Targetable Tumor Suppressive Pathway in T-cell Leukemia. <i>Cancer Discovery</i> , 2016, 6, 972-985.	7.7	33
78	Bromodomain inhibitor OTX015 in patients with acute leukaemia: a dose-escalation, phase 1 study. <i>Lancet Haematology</i> , 2016, 3, e186-e195.	2.2	359
79	Pre-treatment with oral hydroxyurea prior to intensive chemotherapy improves early survival of patients with high hyperleukocytosis in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2016, 57, 2281-2288.	0.6	35
80	A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 139-145.	0.2	60
81	Unlike <i>ASXL1</i> and <i>ASXL2</i> mutations, <i>ASXL3</i> mutations are rare events in acute myeloid leukemia with t(8;21). <i>Leukemia and Lymphoma</i> , 2016, 57, 199-200.	0.6	19
82	Health-Related Quality of Life (HRQoL) of Blinatumomab Versus Standard of Care (SOC) Chemotherapy in Patients with Relapsed or Refractory Philadelphia Negative B-Cell Precursor Acute Lymphoblastic Leukemia in a Randomized, Open-Label Phase 3 Study (TOWER). <i>Blood</i> , 2016, 128, 222-222.	0.6	9
83	Prevention of Venous Thrombotic Events in Adult Patients with Acute Lymphoblastic Leukemia Treated in a Pediatric-Inspired Protocol - a Graall Study. <i>Blood</i> , 2016, 128, 2776-2776.	0.6	4
84	The Upper Age Limit for a Pediatric-Inspired Therapy in Younger Adults with Ph-Negative Acute Lymphoblastic Leukemia (ALL)? Analysis of the Graall-2005 Study. <i>Blood</i> , 2016, 128, 762-762.	0.6	13
85	Retinoic acid and arsenic trioxide trigger degradation of mutated NPM1, resulting in apoptosis of AML cells. <i>Blood</i> , 2015, 125, 3447-3454.	0.6	104
86	Next-generation sequencing of FLT3 internal tandem duplications for minimal residual disease monitoring in acute myeloid leukemia. <i>Oncotarget</i> , 2015, 6, 22812-22821.	0.8	45
87	Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. <i>Lancet Oncology</i> , 2015, 16, 57-66.	5.1	1,031
88	The p16INK4A/pRb pathway and telomerase activity define a subgroup of Ph+ adult Acute Lymphoblastic Leukemia associated with inferior outcome. <i>Leukemia Research</i> , 2015, 39, 453-461.	0.4	8
89	Site- and allele-specific polycomb dysregulation in T-cell leukaemia. <i>Nature Communications</i> , 2015, 6, 6094.	5.8	47
90	Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. <i>Blood</i> , 2015, 125, 3711-3719.	0.6	291

#	ARTICLE	IF	CITATIONS
91	Evolving characteristics and outcome of secondary acute promyelocytic leukemia (<sc>APL</sc>): A prospective analysis by the <sc>F</sc>renchâ€<sc>B</sc>elgianâ€<sc>S</sc>wiss <sc>APL</sc> group. Cancer, 2015, 121, 2393-2399.	2.0	15
92	Impact of additional genetic alterations on the outcome of patients with NPM1-mutated cytogenetically normal acute myeloid leukemia. Haematologica, 2015, 100, e196-e199.	1.7	16
93	Quantification of EVI1 transcript levels in acute myeloid leukemia by RT-qPCR analysis: A study by the ALFA Group. Leukemia Research, 2015, 39, 1443-1447.	0.4	9
94	Liposomal cytarabine in prophylaxis or curative treatment of central nervous system involvement in Burkitt leukemia/lymphoma. Annals of Hematology, 2015, 94, 1859-1863.	0.8	4
95	Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22+ B-acute lymphoblastic leukemia patients: a phase II study. Haematologica, 2015, 100, e128-e131.	1.7	26
96	Targeting IRAK1 in T-Cell acute lymphoblastic leukemia. Oncotarget, 2015, 6, 18956-18965.	0.8	16
97	<i>IDH1/2</i>but not<i>DNMT3A</i>mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the Acute Leukemia French Association. Oncotarget, 2015, 6, 42345-42353.	0.8	92
98	Core-binding factor acute myeloid leukemia in first relapse: a retrospective study from the French AML Intergroup. Blood, 2014, 124, 1312-1319.	0.6	61
99	Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. Blood, 2014, 123, 3739-3749.	0.6	281
100	Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncology, The, 2014, 15, 986-996.	5.1	549
101	Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations. Blood, 2014, 124, 1445-1449.	0.6	105
102	Pediatric-Like Therapy for Adults with ALL. Current Hematologic Malignancy Reports, 2014, 9, 158-164.	1.2	40
103	Management and treatment results in patients with acute promyelocytic leukaemia (APL) not enrolled in clinical trials. European Journal of Cancer, 2014, 50, 1159-1168.	1.3	24
104	Final Analysis of the ALFA 0701 Study. Blood, 2014, 124, 376-376.	0.6	20
105	Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: Results of the ALFA-0701 trial. Oncotarget, 2014, 5, 916-932.	0.8	47
106	MRD assessed by<i>WT1</i>and<i>NPM1</i>transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin. Oncotarget, 2014, 5, 6280-6288.	0.8	71
107	Toward a <i>NOTCH1/FBXW7/RAS/PTEN</i>-Based Oncogenetic Risk Classification of Adult T-Cell Acute Lymphoblastic Leukemia: A Group for Research in Adult Acute Lymphoblastic Leukemia Study. Journal of Clinical Oncology, 2013, 31, 4333-4342.	0.8	202
108	Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. Blood, 2013, 121, 2213-2223.	0.6	313

#	ARTICLE	IF	CITATIONS
109	Superior Long-Term Outcome With Idarubicin Compared With High-Dose Daunorubicin in Patients With Acute Myeloid Leukemia Age 50 Years and Older. <i>Journal of Clinical Oncology</i> , 2013, 31, 321-327.	0.8	68
110	Assessment Of Minimal Residual Disease In Acute Myeloblastic Leukemia In Multiparameter Flow Cytometry. <i>Blood</i> , 2013, 122, 2613-2613.	0.6	1
111	The Addition Of Gemtuzumab Ozogamicin (GO) To Induction Chemotherapy Reduces Relapse and Improves Survival In Patients Without Adverse Risk Karyotype: Results Of An Individual Patient Meta-Analysis Of The Five Randomised Trials. <i>Blood</i> , 2013, 122, 356-356.	0.6	11
112	Prospective Analysis Of Plasma Cholesterol and Triglycerides In Patients (pts) With Chronic Phase (CP)-Chronic Myeloid Leukemia (CML) During Treatment With The 2nd Generation Tyrosine Kinase Inhibitor (TKI) Nilotinib. <i>Blood</i> , 2013, 122, 4042-4042.	0.6	5
113	Lenalidomide (LEN) Combined To Intensive Chemotherapy (IC) In AML and Higher Risk MDS With Del 5q. Results Of a Phase I/II Study Of The Groupe Francophone Des Myelodysplasies (GFM). <i>Blood</i> , 2013, 122, 620-620.	0.6	2
114	Epidemiology Of Invasive Aspergillosis (IA) During Induction Therapy In Adults With Acute Lymphoblastic Leukemia (ALL): A Graall-2005 Study. <i>Blood</i> , 2013, 122, 1394-1394.	0.6	0
115	Arsenic Trioxide (ATO) Or ATRA For Consolidation Treatment Of Standard Risk Non Elderly Newly Diagnosed APLâ€ Second Interim Analysis Of a Randomized Trial (APL 2006) By The French Belgian Swiss APL Group. <i>Blood</i> , 2013, 122, 495-495.	0.6	0
116	Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. <i>Lancet</i> , The, 2012, 379, 1508-1516.	6.3	839
117	Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. <i>Blood</i> , 2010, 115, 453-474.	0.6	2,963
118	Dasatinib (Sprycel®) and Low Intensity Chemotherapy for First-Line Treatment In Elderly Patients with De Novo Philadelphia Positive ALL (EWALL-PH-01): Kinetic of Response, Resistance and Prognostic Significance. <i>Blood</i> , 2010, 116, 172-172.	0.6	15
119	Should Immunosuppressive Therapy (IST) Be Used More Often In Lower Risk MDS?. <i>Blood</i> , 2010, 116, 1868-1868.	0.6	1
120	Prolonged Survival without Complete Remission (CR) In AML Patients (Pts) Treated with Azacitidine (AZA). <i>Blood</i> , 2010, 116, 2183-2183.	0.6	13
121	Arsenic Trioxide (ATO) In the Consolidation Treatment of Newly Diagnosed APL - First Interim Analysis of a Randomized Trial (APL 2006) by the French Belgian Swiss APL Group. <i>Blood</i> , 2010, 116, 505-505.	0.6	3
122	Therapy Related APL (tAPL). Prospective Analysis of Etiological Factors In Recent Cases, and Comparison with De Novo Cases. <i>Blood</i> , 2010, 116, 2171-2171.	0.6	0
123	A Pediatric Treatment of Ph-Negative Acute Lymphoblastic Leukemia (ALL) Is Effective and Safe In Adolescents and Young Adults (AYAs) until 29 Years of Age. <i>Blood</i> , 2010, 116, 2125-2125.	0.6	0
124	Deletion of the Tumor Suppressor Gene NF1 Is Found In 3.5% of 485 De Novo Adult Myeloid Leukemia and Is Correlated with Unfavourable Cytogenetic: On Behalf of the ALFA Group. <i>Blood</i> , 2010, 116, 4171-4171.	0.6	0
125	Early Admission to the Intensive Care Unit In High Risk Acute Myeloid Leukemia Patients. <i>Blood</i> , 2010, 116, 4364-4364.	0.6	0
126	Core binding factor acute myeloid leukemia (CBF-AML): is high-dose Ara-C (HDAC) consolidation as effective as you think?. <i>Current Opinion in Hematology</i> , 2009, 16, 92-97.	1.2	30

#	ARTICLE	IF	CITATIONS
127	New insights in the management of elderly patients with acute myeloid leukemia. <i>Current Opinion in Oncology</i> , 2009, 21, 589-593.	1.1	21
128	NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study. <i>Blood</i> , 2009, 113, 3918-3924.	0.6	207
129	NOTCH1/FBXW7 Mutations, but Not Low ERG/BAALC Expression, Identify a Major Subgroup of Adult T-ALL with a Favorable Outcome: a GRAALL Study.. <i>Blood</i> , 2009, 114, 1568-1568.	0.6	0
130	Prognostic and oncogenic relevance of TLX1/HOX11 expression level in T-ALLs. <i>Blood</i> , 2007, 110, 2324-2330.	0.6	60
131	Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. <i>Blood</i> , 2007, 109, 5129-5135.	0.6	160
132	Cyclin D2 Dysregulation by Chromosomal Translocations to TCR Loci in T-Cell Acute Lymphoblastic Leukemia (T-ALL).. <i>Blood</i> , 2006, 108, 2073-2073.	0.6	0
133	Notch1 Mutations in Adult T Lymphoblastic Lymphoma and T-ALL.. <i>Blood</i> , 2006, 108, 2286-2286.	0.6	0
134	HOXA genes are included in genetic and biologic networks defining human acute T-cell leukemia (T-ALL). <i>Blood</i> , 2005, 106, 274-286.	0.6	331
135	Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia—results of the prospective multicenter LALA-94 trial. <i>Blood</i> , 2002, 100, 2357-2366.	0.6	344
136	Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First Relapse. <i>Journal of Clinical Oncology</i> , 2001, 19, 3244-3254.	0.8	837